Clinical Trial Update: Cadonilimab Combined With S-1 or Capecitabine as Second-line Treatment for Advanced Pancreatic Cancer [Phase 2]

View source ↗

Summary

An ongoing Phase 2 clinical trial is evaluating cadonilimab in combination with S-1 or capecitabine as second-line therapy for advanced pancreatic cancer. The s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Cadonilimab
• Capecitabine (capecitabine)
• S-1 (tegafur/gimeracil/oteracil)

Snippet

Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Conditions: Pancreatic Neoplasms | Phase 2 | Status: RECRUITING